Glynis Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.60 M
as on 29-12-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 0.65 M
as on 29-12-2024
- Revenue 264.38%
(FY 2021)
- Profit 137.50%
(FY 2021)
- Ebitda 113.80%
(FY 2021)
- Net Worth 66.80%
(FY 2021)
- Total Assets 172.75%
(FY 2021)
About Glynis Pharmaceutical
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹0.65 M.
Santu Mondal, Tapan Bera, Sudip Mondal, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24100WB2014PTC204567
- Company No.
204567
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2014
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Nadia, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Glynis Pharmaceutical?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tapan Bera  | Director | 07-Jan-2019 | Current |
| Supriya Santra | Director | 08-Feb-2021 | Current |
| Santu Mondal | Director | 07-Jan-2019 | Current |
| Sudip Mondal | Director | 23-Jul-2019 | Current |
| Moumita Mondal | Director | 25-Jan-2022 | Current |
| Shakyasen Chakraborty | Director | 09-Dec-2014 | Current |
Financial Performance of Glynis Pharmaceutical.
Glynis Pharmaceutical Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 264.38% increase. The company also saw a substantial improvement in profitability, with a 137.5% increase in profit. The company's net worth Soared by an impressive increase of 66.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glynis Pharmaceutical?
In 2021, Glynis Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Glynis Medicare Private LimitedActive 1 year 9 months
Tapan Bera, Supriya Santra and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 18 Jan 2016 | ₹0.65 M | Open |
How Many Employees Work at Glynis Pharmaceutical?
Glynis Pharmaceutical has a workforce of 4 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glynis Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glynis Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
